0000000000668354

AUTHOR

R. Jeffrey Karnes

showing 5 related works from this author

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.

2020

Abstract Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients. Evidence acquisition A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Re…

OncologyBiochemical recurrenceMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyContext (language use)PelvisAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicinePositive nodesInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)ProstatectomyProstate cancerbusiness.industryProstatectomyLymph node; Positive nodes; Prostate cancer; Radical prostatectomyProstatic Neoplasmsmedicine.diseaseRadical prostatectomyRadiation therapySystematic reviewOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionSurgeryLymph nodebusinessEuropean urology oncology
researchProduct

RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT

2017

Bladder cancer BCG T1HG re-TURSettore MED/24 - Urologia
researchProduct

RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER

2017

Bladder cancer T1HG re-TUR BCGSettore MED/24 - Urologia
researchProduct